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ABSTRACT: The von Hippel−Lindau tumor suppressor
protein is the substrate binding subunit of the VHL E3
ubiquitin ligase, which targets hydroxylated α subunit of
hypoxia inducible factors (HIFs) for ubiquitination and
subsequent proteasomal degradation. VHL is a potential target
for treating anemia and ischemic diseases, motivating the
development of inhibitors of the VHL:HIF-α protein−protein
interaction. Additionally, bifunctional proteolysis targeting
chimeras (PROTACs) containing a VHL ligand can hijack
the E3 ligase activity to induce degradation of target proteins.
We report the structure-guided design and group-based optimization of a series of VHL inhibitors with low nanomolar potencies
and improved cellular permeability. Structure−activity relationships led to the discovery of potent inhibitors 10 and chemical
probe VH298, with dissociation constants <100 nM, which induced marked HIF-1α intracellular stabilization. Our study
provides new chemical tools to probe the VHL-HIF pathways and new VHL ligands for next-generation PROTACs.
■ INTRODUCTION
Proteins are constantly synthesized and targeted for degrada-
tion during cellular homeostasis. The major pathway to protein
degradation is the ubiquitin−proteasome system (UPS), ﬁrst
reported in the early 1980s.1 In a highly regulated enzymatic
signaling cascade, ubiquitin is covalently attached to a substrate
protein as a monomer or as a polyubiquitin chain, promoting
proteasome-catalyzed target degradation.2,3 The complexity and
biological importance of the UPS, together with implication of
this pathway in a wide range of diseases, highlight its
importance as a therapeutic target.4,5 The market release of
the pioneering proteasome inhibitors bortezomib and carﬁlzo-
mib, for the treatment of hematopoietic and lymphoid
malignancies, validated the UPS as a focus for therapeutic
intervention and opened the door to a new series of
proteasome inhibitors.5−7 Despite their success, proteasome
inhibitors lack substrate speciﬁcity, which is a signiﬁcant
limitation to their use as chemical probes of speciﬁc biological
pathways and leads to unwanted side eﬀects in their use as
drugs.7,8
Speciﬁc binding of a target substrate to an E3 ubiquitin ligase
is required for substrate ubiquitination and is therefore a key
step in the ubiquitination process.3,9 E3 ubiquitin ligases
determine speciﬁcity of substrate ubiquitination and thus could
be regarded as more attractive targets to center drug discovery
eﬀorts over the proteasome. However, small-molecule modu-
lators of E3 ligases need to target protein−protein interactions
(PPIs), either directly or allosterically.10 The typically ﬂat and
featureless nature of many PPI interfaces can be a limiting
factor in the development of potent and selective inhibitors.11,12
To cover considerable protein surface area that often lacks well-
deﬁned pockets, most PPI inhibitors tend to be larger in size
than classical enzyme inhibitors or receptor antagonists, forcing
medicinal chemists to break conventional drug-like quality
metrics.13−15 These observations consequently led to E3 ligases
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being perceived as untractable target space.16 On the other
hand, the identiﬁcation of small-sized hotspots for certain PPIs,
particularly those characterized by the recognition of primary-
type linear epitopes, has led to the successful observation of
small-molecule-sized patches on protein surfaces that could be
adequately targeted by drug-like molecules.17−19 Today, several
small molecules that modulate PPIs have been developed as
chemical probes, and many have entered clinical trials.19,20
These realizations have reinvigorated drug discovery eﬀorts for
a wide range of PPI-based targets, including E3 ubiquitin
ligases.21
The von Hippel−Lindau protein (VHL) is a member of the
Cullin-RING ligase family of E3 ubiquitin ligases.21 The major
substrate of VHL is the hypoxia inducible factor 1α (HIF-1α), a
transcription factor that drives the transcriptional program of
many human genes,22 mainly involved in hypoxia adapta-
tion.23,24 When tissue oxygen levels are normal, HIF-1α
expression levels are tightly controlled. Iron- and oxygen-
dependent hydroxylation occurs at two speciﬁc proline residues
within the HIF-1α oxygen-dependent degradation domain
(ODD) by prolyl hydroxylase domain (PHD) enzymes. This
modiﬁcation leads to HIF-1α speciﬁc recognition and
ubiquitination by VHL and subsequent degradation via the
UPS (Supporting Information, Figure 1).25−28
The importance of this pathway has been uncovered in a
wide range of diseases, including conditions characterized by
anemia, ischemia, inﬂammation, chronic neurodegeneration,
and more recently mitochondrial dysfunction.29−32 Small-
molecule inhibition of this pathway could activate HIF-1α
expression, upregulating genes involved in the hypoxic
response, consequently providing a potential therapeutic
strategy. Indeed, small-molecule PHD inhibitors have been
developed that have shown potential in a number of
pathologies.33−35 Among these, the candidate FG-4592 (N-
[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-
glycine, also known as roxadustat or ASP1517) has progressed
to a phase III clinical trial to evaluate eﬃcacy and safety in
hemodialysis chronic kidney patients with anemia.36,37 Despite
their clinical potential, no PHD inhibitor shows selectivity
between the three diﬀerent PHD paralogues (PHD1, PHD2,
and PHD3).38 In addition, several non-HIF substrates of PHD
enzymes have been identiﬁed.39,40 Lack of selectivity could
promote unwanted side eﬀects due to the diﬀerent substrate
speciﬁcities as well as cellular and tissue localization of PHD
enzymes.38
In contrast to PHD inhibitors, inhibitors of the VHL:HIF-1α
PPI would allow blocking the pathway downstream of HIF
hydroxylation by PHD enzymes.41 This approach could avoid
HIF-independent oﬀ-target eﬀects and deliver new lead
compounds as hypoxia mimetics.42 To validate the chemical
intervention on VHL and establish the biological consequences
of modulating its activity, small molecules must eﬀectively
penetrate cells and engage with VHL with enough potency to
productively block HIF-1α binding. In a diﬀerent approach,
VHL ligands can be conjugated to target ligands of interest to
design VHL-recruiting bivalent chimeric ligands (also known as
PROTACs).43 PROTACs can eﬃciently hijack the VHL ligase
to induce intracellular degradation of the desired target
proteins. Previous work from our laboratory and others have
demonstrated potent and selective activities of VHL-recruiting
PROTACs against a wide range of target proteins, including
Brd4,44−48 RIPK2,49 and c-Abl kinase among others.50
Co-crystal structures of VHL bound with a hydroxyproline
peptide from human HIF-1α carboxy-terminal oxygen-depend-
ent degradation (CODD) motif identiﬁed a groove on the
pVHL surface, which accommodated the substrate peptide.28,51
Recognizing that this primary type PPI could be suitably
targeted by small-molecule disruptors, in pioneering work, our
laboratory in collaboration with the Crews laboratory
developed a ﬁrst-generation of VHL ligands with single-digit
micromolar binding aﬃnities based around the central
hydroxyproline core fragment.17,52−54 However, these initial
compounds proved inactive as PPI inhibitors in cells.
Subsequent structure-guided optimization led to more potent
inhibitors with improved nanomolar binding aﬃnities.55 The
best inhibitor of this series, compound 1 (VH032, Figure 1A)
was able to disrupt the VHL:HIF-1α PPI in cells, illustrated by
its capacity to stabilize hydroxylated HIF-1α.41 Nevertheless,
this inhibitor showed low passive cell permeability and
exhibited a large mismatch between in vitro potency in solution
and in cells.41
Motivated by a desire to drive further inhibitor optimization,
analysis of the X-ray crystal structure of the complex composed
of VHL, elongin B, and elongin C (VBC) with 1 suggested an
attractive pocket at the left-hand side (LHS) of the VHL:HIF
interface that was only partially ﬁlled by the terminal acetamide
group of 1 and could therefore provide space to further grow
and optimize the molecule (Figure 1A). Herein, we describe a
systematic group-based optimization of VHL inhibitors starting
from 1, improving binding aﬃnity, cell membrane passive
permeability, and ultimately cellular activity, a campaign that
led to the discovery of inhibitor 15 (VH298), a potent and
selective probe of the hypoxia HIF-1α pathway.41
■ RESULTS AND DISCUSSION
VHL Inhibitor SAR. We aimed to optimize the
physicochemical properties and binding aﬃnity of VHL
Figure 1. Initial optimization strategy. (A) X-ray crystal structure of
VHL, elongin B, and elongin C (VBC) protein complex with inhibitor
1 (purple carbons, PDB 4W9H).55 VHL is shown as a pale-green
surface and the VHL residues forming the binding pocket as orange
stick representations. (B) Designed group modiﬁcations on inhibitor 1
to improve activity.
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inhibitors in order to minimize the observed mismatches
between biophysical and cellular potency.41 The information
gathered from the co-crystal structure of inhibitor 1 bound to
VBC protein complex oﬀered a starting point for the design of
a new series of inhibitors by adding small modiﬁcations on the
LHS of the inhibitor (Figure 1A).
In the ﬁrst new series of inhibitors, we decided to keep the
carbonyl on the LHS in order to maintain the hydrogen bond
between this group and the structural water in this pocket. Our
design strategy was to replace the three hydrogens of the
acetamide methyl group, one at a time, using alkyl groups to
better ﬁll the LHS pocket or adding electron-withdrawing
groups at the α position of the LHS amide in order to lock its
conformation.56,57 It was also decided to evaluate the eﬀect of
removing the LHS acetamide hydrogen-bond donor group
(NH) via cyclization, which we hypothesized could improve
cellular permeability (Figure 1B).58 The synthesized com-
pounds were evaluated biophysically in a direct binding assay
using isothermal titration calorimetry (ITC) and for their
ability to displace a high-aﬃnity HIF peptide using ﬂuorescence
polarization (FP). In parallel, the compounds cellular activity
was evaluated in HeLa cells by monitoring protein levels of
HIF-1α using Western blot (Table 1).
Substitution of a single hydrogen on the acetamide group for
a hydroxyl (3) maintained binding aﬃnity but led to a
substantial loss in cellular potency. On the other hand,
expansion of the alkyl chain from methyl to ethyl (4) allowed
the retention of inhibitor cellular potency despite a 2-fold loss
in inhibitor binding aﬃnity. These two observations suggested
that tuning hydrogen bond donors and lipophilicity could play
as important a role as binding aﬃnity in determining cellular
activity. Replacing all three hydrogens with ﬂuorine (7) or
chlorine groups (8) did not impact binding aﬃnity and cellular
potency. In contrast, introduction of a bulky tert-butyl group
(5) resulted in a loss in binding aﬃnity and in cellular potency,
a similar eﬀect observed when replacing all hydrogens for two
methyl groups together with one ﬂuorine group (9). However,
substitution of two hydrogens with a restrained cyclopropyl
group (6) promoted a small improvement in both binding
aﬃnity and cellular activity. Further replacement of the tertiary
hydrogen of 6 with a ﬂuorine (10) led to a marked increase in
both binding aﬃnity and cellular potency compared to 1 and 6
Table 1. Chemical Structure, FP Kds Back-Calculated from IC50s,
17 ITC Measured Kds, and Group Eﬃciencies (GE) [Based on
FP Results and Calculated as GE = ΔpKd/ΔHA (Heavy Atoms)] of Inhibitors 1 and 2−12
aHeLa cells were treated with 50 μM of the respective inhibitor and HIF-1α stabilization levels were measured by Western blot after 2 h treatment
(protein levels normalized to HIF-1α stabilization level observed with 1).
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(Table 1). Figure 2 illustrates representative ITC and FP
binding curve for 10, the most potent inhibitor of the series,
and the parent inactive epimer cis-10, which due to a change in
the proline OH group orientation no longer binds to VHL.
Attempts to modify other regions of the chemical structure
of 1 did not yield improvements. For example, modiﬁcation of
the tert-leucine side chain for a less bulky alanine side chain
(11), or removal of the acetamide hydrogen bond donor group
through cyclization into a pyrrolidinone (12) led to signiﬁcant
loss of inhibitor binding aﬃnity and cellular potency. Last,
acetamide methyl group substitution for a Boc protecting group
(2) was not tolerated, resulting in the greatest loss in binding
and cellular potency.
To better understand the SAR of this new inhibitor series,
the X-ray crystal structures of inhibitors 3, 6, 10, and 11 bound
to VBC were obtained. All solved structures revealed a
conserved inhibitor binding mode at the VHL:HIF interface
(Figure 3), consistent with the binding of 1.55 The crystal
structure of 3 shows two diﬀerent conformations upon binding
to VBC, each with 50% of occurrence. In the ﬁrst inhibitor
conformation, the added OH group points upward, forming an
extra hydrogen bond with a structural water that promotes the
formation of an interaction network between Tyr112 side chain
and the amide carbonyl on the LHS of inhibitor’s hydroxypro-
line (Hyp) (Figure 3A). In the second conformation, the
hydroxyl group formed a bidentate interaction with the
structural water present on the far left side of the binding
pocket, together with LHS amide carbonyl (Figure 3B). These
favorable interactions contribute to a small improvement in
inhibitor binding aﬃnity (Table 1).
Crystal structures of 6 (Figure 3C) and 10 (Figure 3D)
showed the cyclopropyl group occupying the far LHS of the
VHL−HIF interface, maintaining the hydrogen bond inter-
actions with the structural water. The addition of cyclopropyl
induces a conformational modiﬁcation in the residues on this
side of the pocket to accommodate this moiety. The most
notable conformational change is observed on the side chain of
Arg69, which adopts a bent conformation to accommodate the
new group on the LHS. From the crystal structure of inhibitor
10, the ﬂuorine atom at the α position is found anti to the
amide carbonyl. This matches a known minimum-energy
conformation for α-ﬂuoroamides.56,57 This eﬀect allows the
inhibitor to be preorganized in its bound conformation prior to
binding, thus minimizing the entropic penalty to binding and as
a result increasing binding aﬃnity.
Substitution of the tert-leucine group for a less bulky alanine
in 11 was meant to more closely mimic the sequence of the
HIF-1α peptide (Supporting Information, Figure 2). This
modiﬁcation however led to a less rigid conformation on the
inhibitor LHS. In the co-crystal structure of 11 (Figure 3E), the
ligand bends upward, increasing the distance between the
acetamide carbonyl and the structural water from 2.8 ± 0.1 to
3.8 ± 0.5 Å (Supporting Information, Figure 3), consequently
weakening this hydrogen bond and decreasing the binding
aﬃnity.
The ﬁrst inhibitor series led us to the discovery of 10, a VHL
inhibitor with double-digit nanomolar binding aﬃnity, good cell
membrane permeability, and high activity in cells (Table 1 and
Figure 4A), which are some of the key parameters needed for a
good chemical probe.59 Despite meeting these benchmarks,
further investigation revealed a degree of cytotoxicity for 10,
which notably decreased cell proliferation relative to DMSO
vehicle (Figure 4B,C). The inactive epimer cis-10 still presented
a degree of cytotoxicity (Figure 4B,C). Together, these ﬁndings
suggested an oﬀ-target toxicity for 10 (Figure 4).
The observed cytotoxicity of 10 motivated us to identify a
more suitable chemical probe. On the basis of the information
furnished by the co-crystal structure, we designed a second
series of VHL inhibitors (Figure 5).
In this second series, we initially studied the impact of
changing the ﬂuorine atom for other electron withdrawing
groups or promoters of intramolecular hydrogen bonds.
Figure 2. Biophysical characterization of inhibitor 10 binding to VBC. (A) Competitive FP binding assay curve, monitoring the displacement of a
20-mer FAM-labeled HIF-1α peptide bound from VBC by inhibitor 10 (Kd = 3 nM). (B) ITC titrations of 300 μM inhibitor 10 (blue) or 300 μM of
its cis inactive epimer (green) into 30 μM VBC protein.
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Second, to exploit the ﬂexibility of Arg69 in the LHS pocket, we
expanded the cyclopropyl ring by adding larger and more
lipophilic groups. In addition, we considered moieties that
could potentially form a hydrogen bond with the Arg69 side
chain or, alternatively, together with the LHS carbonyl amide,
could form bidentate hydrogen bonds with the structural water
present in the LHS pocket. Finally, we decided to test the
impact of methylating the solvent-exposed NH group of the
LHS acetamide and of replacing the tert-leucine side chain for
threonine to explore potential hydrogen bonds at the top LHS
pocket, as observed previously (Figure 5B).53
Removing the hydrogen bond donor group through
methylation (13) resulted in a major loss in binding aﬃnity
and cellular potency when compared with 1, presumably due to
destabilization of the required trans-amide bond conformation.
Substitution of tert-leucine on 10 for a threonine (14) side
chain group also led to a loss in binding aﬃnity and cellular
activity. Conversion of the ﬂuorine group into an electron-
withdrawing group such a cyano (15) revealed a 2-fold increase
in binding aﬃnity and in cellular potency compared to 1.
Changing the ﬂuorine group for a ketone moiety (16) also
improved both binding aﬃnity and cellular activity. Mod-
iﬁcation of the ﬂuorine atom with an acetamide (17) retained a
comparable aﬃnity when compared with 1 but yielded a
considerable loss in cellular potency, presumably as a result of
poorer cell membrane passive permeability. Expansion of the
cyclopropyl ring into a cyclobutyl (18) led to a small loss of
inhibitor binding aﬃnity but a greater cellular activity,
presumably due to the increased lipophilicity and permeability.
Conversion of the cyclopropyl group into an oxetane (19)
retained binding aﬃnity but led to a 4-fold loss in cellular
activity. Further conversion of the cyclopropyl group into a
cyclobutanone (20) or into an acetylated azetidine (21) led to
a 2- and 20-fold loss in binding aﬃnity and a 5- and 11-fold
decrease in cellular potency, respectively.
In summary, while we were not able to improve binding
aﬃnity beyond that of inhibitor 10, most of the designed
inhibitors retained in vitro binding potencies around 100 nM
and also retained high cellular activity, in many cases greater
than starting inhibitor 1. In particular, 15 and 10 were the only
compounds that showed Kd < 100 nM and positive group
eﬃciencies (Table 2). Inhibitor 15 was shown to be highly cell
permeable (vide infra, Table 3) and exhibited cellular activity
comparable with 10 and signiﬁcantly greater than 1. Further
investigation with 15 revealed no toxicity in cells (Figure 6),
supporting further evaluation of it as a chemical probe.
To support the SAR results of the second inhibitor series, the
X-ray crystal structures of 15 and 16−19 bound to VBC were
Figure 3. Co-crystal structures of ﬁrst-series inhibitors. Crystal structures of VBC in complex with 3 (A,B), 6 (C), 10 (D), and 11 (E). VHL
inhibitors are shown as sticks with purple carbons. VHL is shown as a pale-green surface and the VHL residues forming the binding pocket as orange
stick representations. Inhibitor-binding waters are shown as red spheres. Hydrogen bond interactions between inhibitors, bound waters, and VHL
pocket residues are shown as dashed red lines.
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obtained. These crystal structures revealed that most of the key
interactions and structural features observed for 10 were
maintained. Described herein are the key changes in
interactions observed at the LHS from the diﬀerent groups.
The cyano group on inhibitor 15 (Figure 7A) forms a hydrogen
bond with a water molecule that allows the formation of a water
network similar to the one observed in the crystal structure
with inhibitor 3 bound (Figure 3A). In the crystal structure of
inhibitor 16 (Figure 7B), the ketone adopts an optimal distance
(2.5 ± 0.1 Å) and acceptable orientation (angles formed
between the CO bond and amide nitrogen of 90.7 ± 2.0°
and between the C−N bond and ketone oxygen of 91.5 ± 0.8°)
for the formation of an intramolecular hydrogen bond with the
NH of inhibitor LHS amide (Supporting Information, Figure
5).60 The observed intramolecular interaction could stabilize
the conformation of the LHS of the inhibitor, improving aﬃnity
and cell permeability, thus contributing to the observed high
cellular activity.61,62
The crystal structure of 17 (Figure 7C) did not show any
major changes in the ligand binding mode and in the
conformation of pocket residues when compared with the
crystal structure of the ﬂuoro-analogue 10 (Figure 3C). The
terminal acetamide of 17 points upward toward the solvent, not
forming any new interactions with the protein nor an
intramolecular hydrogen bond with the NH of the LHS
inhibitor amide. These features, together with the extra amide
H-bond donor group, likely account for the poor cellular
activity of 17 (Table 2).
The structure of inhibitor 18 bound to VBC did not reveal
any critical changes in either the ligand or pocket residue
conformations (Figure 7D). The cyclobutyl moiety ﬁlls the far
LHS of the pocket, inducing a conformational change to the
side chain of Arg69, as previously described.41 Replacement of
the cyclobutyl with an oxetane group in inhibitor 19 showed
that the ether oxygen was able to replace the LHS amide in the
ability to form a hydrogen bond with the LHS structural water
(Figure 7E). A hydrogen bond interaction from the oxetane
oxygen (2.9 ± 0.1 Å distance) leads to an increase in the
distance between the amide carbonyl oxygen and the structural
water (3.7 ± 0.2 Å) (Supporting Information, Figure 6). This is
incompatible with the bidentate interaction mode previously
observed with inhibitor 3, a result of the increased distance
between the two oxygen atoms in 19 relative to 3 and the steric
constraints of the oxetane ring.
In summary we describe a group-based optimization of 1 that
led us to the discovery of a more potent inhibitor 10. Further
Figure 4. Cellular activity and toxicity of 10. (A) Activity of inhibitor 10 in HeLa cells expressing a hypoxia responsive element (HRE)-luciferase
reporter and treated with indicated concentrations for 24 h. Luminescence reports luciferase expression as proxy of HIF-α activity.41 Colony
formation (B) and cell-proliferation assays (C) showing toxicity in HeLa cells after treatment with 150 μM of inhibitor 10 and its cis epimer.
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optimization led us to the discovery of inhibitor 15 which
showed equivalent cellular potency when compared with 10
and was not cytotoxic in cells.
Chemistry. Intermediate 22, 24, and 27 were obtained
following the protocol previously described by us.41,55
Intermediate 22 was used for the synthesis of ﬁnal inhibitors
4 and 6−8 via acylation or inhibitors 3, 5, 9, 10, and 16−20 by
amide coupling reaction (Scheme 1). Further treatment of
intermediate 22 with 4-chlorobutanoyl chloride, followed by
intramolecular cyclization, led to the synthesis of inhibitor 12
(Scheme 1). Reductive amination of 22 with formaldehyde
followed by acylation yielded inhibitor 13 (Scheme 1). An
amide coupling reaction between intermediate 22 and 1-(tert-
butoxycarbonyl)azetidine-3-carboxylic acid led to the inter-
mediate 23, which after deprotection, followed by acylation,
yielded inhibitor 21 (Scheme 1).
Intermediates 25 and 26 were obtained from intermediate 24
after deprotection with triﬂuoroacetic acid followed by amide
coupling reaction with L-alanine or L-threonine, respectively.
Final inhibitors 11 and 14 were obtained from intermediates 25
and 26 after their deprotection followed by acylation or amide
coupling reaction, respectively (Scheme 2).
The cis epimer of inhibitor 10 was obtained from
intermediate 27 following the same synthetic pathway used
for its trans conformer, using Boc-Hyp cis epimer to obtain the
desired ﬁnal inhibitor (Scheme 3).
Evaluation of VHL Inhibitor Permeability and Binding
Kinetics. Cell membrane passive permeability is known to have
an important role in inhibitor optimization, as it can lead to an
increase in intracellular concentration of inhibitor available to
interact with the desired target, which would be expected to
increase cellular activity. Optimization of lipophilicity at
physiological pH, topological polar surface area (TPSA), and
number of rotatable bonds are known to directly impact cell
membrane passive permeability.63,64 From the SAR results, it
was possible to observe that the increase in cellular potency was
not only related with the increase of inhibitor binding aﬃnity to
VBC (Figure 8A). Therefore, to evaluate how lipophilicity and
cell membrane passive permeability contributed to VHL
inhibitors activity in cells, these parameters were experimentally
measured for a selection of the most potent inhibitors (Table
3).
Inhibitors 10 (LE = 0.27, LLE = 5.73), 15 (LE = 0.26, LLE =
5.65), and 16 (LE = 0.25, LLE = 5.63) with permeabilities of
27.1, 19.4, and 15.0 nm/s, respectively, were found to be the
most permeable inhibitors. At the other extreme were inhibitors
3 (LE = 0.27, LLE = 6.28), 17 (LE = 0.24, LLE = 6.28), and 19
(LE = 0.25, LLE = 5.92) with the lowest permeability values. A
direct relationship was observed between inhibitor perme-
ability, lipophilicity, and activity in cells (Figure 8B,C).
Inhibitors 6, 10, 15, 16, and 18 were found to be more
lipophilic than starting inhibitor 1, contributing to their higher
cellular permeability, which was thus reﬂected in their
reasonable intracellular free compound concentration (Sup-
porting Information, Table 1) that leads to a higher cellular
potency.66 In contrast, analysis of TPSA, number of rotatable
bonds, and number of hydrogen bond donors (HBDs) revealed
no correlation with cell permeability (Table 3). Because of
limitation of our PPI-targeting pharmacophore, these param-
eters in VHL inhibitors closely approach the maximal limits for
desired membrane permeability (TPSA < 140 Å2, HBDs <
5).64,67 Clearly, for the most active inhibitors, these high values
are compensated for by a higher lipophilicity, resulting in an
overall increase of inhibitors permeability and activity in cells.
The data, however, suggests that careful monitoring of these
parameters is warranted. For example, adding an extra HBD
group (from 3 to 4) in inhibitors 3 and 17 led to marked
decrease in permeability and cellular potency compared to 1,
despite the comparable CHILogD7.4 values (Tables 2 and 3).
Similarly, breaking beyond TPSA of 140 Å2 in inhibitor 17
resulted in the lowest cell permeability and cellular activity
amonst the tested inhibitors (Tables 2 and 3). These results
argue for close monitoring of all these physicochemical
properties during optimization of a PPI inhibitor.
In addition to permeability and binding aﬃnity, binding
kinetics are also key parameters that can inﬂuence cellular
activity. Longer drug residence at the target can promote the
duration of pharmacological on-target eﬀect. To evaluate how
the binding kinetics could inﬂuence VHL inhibitor activity in
cells, binding kinetics parameters were determined by surface
plasmon resonance for 1, 10, 15, 16, and 18, which all showed
high passive membrane permeability and high potency in cells
(Table 4). The binding experiments were performed at 10 and
20 °C in order to compare the kinetics and aﬃnity of the
inhibitors at diﬀerent temperatures.
A close relationship was observed between dissociation rate
constants and dissociation constants from VBC. Inhibitors 10,
15, and 16, with higher binding aﬃnity than 1, also showed
slower dissociation rates relative to 1 (Table 4). After
comparison of the dissociative half-life (from VBC complex)
of these inhibitors, it was possible to observe higher
dissociation times correlate with higher cellular potencies.
Inhibitor 10 and 15, the most active inhibitors in cells, had the
highest dissociation half-lives among the compounds evaluated
(Figure 9). It is worth pointing out that even the slowest oﬀ
rates measured for our VHL inhibitors are still relatively fast
overall. The resulting residence times are consequently all on
the order of seconds, rather than minutes, suggesting that there
Figure 5. Second series optimization strategy. (A) X-ray crystal
structure of VBC protein complex with inhibitor 10. VHL is shown as
a pale-green surface and the VHL residues forming the binding pocket
as orange stick representations. (B) Designed group modiﬁcations on
inhibitor structure to improve inhibitor activity and optimize inhibitors
toward a chemical probe.
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is much scope to optimize this parameter in the future.
Nevertheless, our data suggests that even these relatively short
residence times suﬃce for a pharmacological eﬀect on VHL, as
shown with other drug−target interactions.69
To begin to assess potential metabolic liabilities and inform
potential use on animal models, we evaluated the microsomal
and plasma stability of the most promising VHL inhibitors
(Table 4). The data revealed slow microsomal clearance (0.7−
3.1 mL × min−1 × g−1) and high plasma metabolic stability
(inhibitors half-life >180 min) with all inhibitors, supporting
their use as chemical probes in vivo in animal models.
Overall, the data support 15 as optimal inhibitor, with high
binding aﬃnity and cellular potency, good cell membrane
permeability, slow dissociation from its target, low toxicity in
cells, and excellent stability. On the basis of these results, 15
was elected as a novel chemical probe selectively blocking VHL
in the hypoxia-signaling pathway downstream of HIF
hydroxylation.41 The compound is available on the “Chemical
Probes Portal” (http://www.chemicalprobes.org).59
■ CONCLUSIONS
We report the structure-guided optimization of a new series of
ligands targeting the VHL E3 ubiquitin ligase. The best
inhibitors have shown aﬃnities in the nanomolar range and
have on-target cellular activity. An increase in inhibitor
lipophilicity yielded a higher cell membrane passive perme-
ability, which together with slower dissociation rate constants
(koff) and increased inhibitor/VBC dissociation half-times
(t1/2), clearly led to increased cellular potency. Additionally,
the most promising inhibitors have also shown excellent
microsomal and plasma stability, supporting their use in vivo
with animal models. Our best inhibitors 10 and 15, to our
knowledge, are the ﬁrst inhibitors to reach double-digit
nanomolar aﬃnities for binding to VHL, as well as the most
potent inhibitors of the VHL:HIF-1α PPI inside cells reported
to date. Inhibitor 15 was elected as the ﬁnal chemical probe
(http://www.chemicalprobes.org/vh298). The compound, and
its inactive cis epimer, are now available from various
commercial vendors.
Our work revealed new VHL inhibitors that can act as probes
of the hypoxia signaling pathway, an approach recently
validated by us.41 Future optimization of in vivo activity is
Table 2. Chemical Structure, FP Back-Calculated Kds, ITC Measured Kds, and Group Eﬃciencies (GE) [Based on FP Results
and Calculated as GE = ΔpKd/ΔHA (Heavy Atoms)] of Inhibitors 1, 10, and 13−21a
aHeLa cells were treated with 50 μM inhibitors and HIF-1α stabilization levels were measured by Western blot after 2 h treatment (protein levels
normalized to HIF-1α stabilization level observed with 1).
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warranted, which could provide lead compounds with an
alternative mode of action as potential therapeutics against
diseases where mimicking a hypoxic response has proven to be
beneﬁcial. Additionally, the reported novel VHL ligands can be
explored for the design of improved VHL-recruiting bifunc-
tional chimeric molecules (PROTACs) to eﬃciently hijack the
VHL E3 ubiquitin ligase to induce intracellular degradation of
target proteins.44,46,49 Importantly, we provide an exemplary
study for optimizing PPI-targeting E3 ligase ligands via similar
strategies, which could inspire current and future eﬀorts to
develop inhibitors or PROTACs against other E3 ligases.
■ EXPERIMENTAL SECTION
Chemistry. Materials and Methods. Commercially available
starting reagents for each reaction were purchased from Sigma-
Aldrich, Fluorochem, Apollo Scientiﬁc, or Manchester Organics and
used without further puriﬁcation. All reactions were carried out using
anhydrous solvents. Analytical thin-layer chromatography (TLC) was
performed on precoated TLC plates (layer 0.20 mm silica gel 60 with
ﬂuorescent indicator (UV 254: Merck)). The TLC plates were air-
dried and revealed under UV lamp (254/365 nm). Flash-column
chromatography was performed using prepacked silica gel cartridges
(230−400 mesh, 40−63 mm; SiliCycle) using a Teledyne ISCO
Combiﬂash Companion or Combiﬂash Retrieve using the solvent
mixtures stated for each synthesis as mobile phase.
Liquid chromatography−mass spectrometry (LC-MS) analyses
were performed with either an Agilent HPLC 1100 series connected
to a Bruker Daltonics MicroTOF or an Agilent Technologies 1200
series HPLC connected to an Agilent Technologies 6130 quadrupole
spectrometer or a Waters 2795 connected to a Waters ZQ Micromass
spectrometer, where all instruments were connected to a diode array
detector. All the ﬁnal compounds used in all the experiments were
evaluated after preparative LC-MS separations with a Waters X-bridge
C18 column (50 mm × 2.1 mm × 3.5 mm particle size); ﬂow rate, 0.5
mL/min with a mobile phase of water/MeCN + 0.1% CHOOH or
water/MeCN + 0.1% NH3; 95/5 water/MeCN was initially held for
0.5 min followed by a linear gradient from 95/5 to 5/95 water/MeCN
over 3.5 min which was then held for 2 min. The purity of all the
compounds was evaluated using the analytical LC-MS system
described before and yield a purity >95%.
High-resolution electrospray measurements were performed on a
Bruker Daltonics MicroTOF mass spectrometer. 1H NMR and 13C
NMR spectra were recorded on a Bruker Avance II 500 spectrometer
(1H at 500.1 MHz, 13C at 125.8 MHz) or on a Bruker DPX-400
cryospectrometer (1H at 400.1 MHz, 13C at 101 MHz). Chemical
shifts (δ) are expressed in ppm reported using residual solvent as the
internal reference in all cases. Signal splitting patterns are described as
singlet (s), doublet (d), triplet (t), multiplet (m), or a combination
thereof. Coupling constants (J) are quoted to the nearest 0.1 Hz.
Intermediates 22, 24, and 27, and ﬁnal inhibitors 1 and 15 were
synthesized as described elsewhere.41,55
General Methodology for the Synthesis of VHL Inhibitors
3−11, 13−21, cis-10, and Intermediates 23, 25, and 26. General
Method A (Synthesis by Acylation). A solution of compound 2 (100
mg, 0.19 mmol) in 1:1 TFA:DCM (6 mL) was stirred at room
temperature for 30 min. The solvents were evaporated under reduced
pressure to give the corresponding deprotected intermediate (TFA
salt−22) as a brown oil that was used in the following reactions
without further puriﬁcation (102 mg, 0.19 mmol). To a solution of the
deprotected intermediate 22 (102 mg, 0.19 mmol, 1 equiv) in DCM
was added triethylamine (57 mg, 79 μL, 0.57 mmol, 3 equiv). After
stirring the mixture for 10 min at room temperature, acetic anhydride
derivative (1.5 equiv) was added and the resulting mixture was then
stirred 2 h at room temperature. The solvents were evaporated under
reduced pressure to aﬀord the corresponding crude compound that
was puriﬁed by ﬂash column chromatography using a gradient of 10%
to 70% acetone in heptane to yield the ﬁnal compounds as solids.
General Method B (Synthesis by HATU Assisted Amide Coupling).
A solution of compound 2 (100 mg, 0.19 mmol) in 1:1 TFA:DCM (6
mL) was stirred at room temperature for 30 min. The mixture was
evaporated under reduced pressure to give the corresponding
deprotected intermediate (TFA salt−22) as a brown oil without
further puriﬁcation (102 mg, 0.19 mmol). To a solution of the
deprotected intermediate 22 (102 mg, 0.19 mmol, 1 equiv) in DMF
was added the carboxylic acid derivative (1 equiv). DIPEA (97 mg, 129
μL, 0.75 mmol, 4 equiv) was added dropwise, and the mixture was
stirred for 5 min at room temperature. HATU (78 mg, 0.21 mmol, 1.1
equiv) was added, and the mixture was stirred at room temperature for
Figure 6. Inhibitor 15 is not cytotoxic. Colony formation (A) and cell-proliferation assays (B) showing no toxicity in HeLa cells after treatment with
150 μM of inhibitor 15 and its cis epimer.
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1 h. Water was added, and the mixture was extracted with ethyl acetate
(3×). The combined organic phases were washed with brine (2×),
dried over MgSO4, and evaporated to aﬀord the corresponding crude
compound that was puriﬁed by ﬂash column chromatography using a




mide (3). Following the general synthesis method B, from
intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and 2-hydroxyacetic
acid (14 mg, 0.19 mmol, 1 equiv), compound 3 was obtained as a
white powder (46 mg, 0.094 mmol, 50%). 1H NMR (CD3OD, 400
MHz): δ 9.32 (s, 1H), 7.52−7.46 (m, 5H), 4.71−4.69 (m, 1H), 4.60−
4.54 (m, 2H), 4.50−4.49 (m, 1H), 4.37 (d, 1H, J = 16.0 Hz), 4.06−
3.96 (m, 2H), 3.89 (d, 1H, J = 12.0 Hz), 3.80 (dd, 1H, J = 12.0, 4.0
Hz), 2.53 (s, 3H), 2.27−2.21 (m, 1H), 2.11−2.05 (m, 1H), 1.04 (s,
9H). 13C NMR (CD3OD, 101 MHz): δ 174.4, 171.8, 154.3, 141.2,
130.5, 130.4, 130.0, 129.7, 129.1, 71.0, 69.0, 62.4, 60.8, 58.1, 43.7, 39.0,
37.2, 26.9, 14.6. HRMS (ESI) m/z: [M+ + 1] calculated for




(4). Following the general synthesis method A, from deprotected
intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and propionic
anhydride (37 mg, 0.28 mmol, 1.5 equiv), compound 4 was obtained
as a white powder (50 mg, 0.10 mmol, 55%). 1H NMR (CDCl3, 500
MHz): δ 8.67 (s, 1H), 7.37−7.32 (m, 5H), 6.15 (d, 1H, J = 8 Hz),
4.69 (t, 1H, J = 10.0 Hz), 4.56−4.50 (m, 3H), 4.33 (dd, 1H, J = 15.0,
5.0 Hz), 4.04 (d, 1H, J = 10 Hz), 3.61 (dd, 1H, J = 10.0, 5.0 Hz),
2.52−2.47 (m, 4H), 2.24−2.18 (m, 2H), 2.14−2.09 (m, 1H), 1.11 (t, J
= 10.0 Hz, 3H), 0.93 (s, 9H). 13C NMR (CDCl3, 125 MHz): δ 174.5,
172.0, 170.9, 150.5, 148.6, 138.2, 131.7, 131.1, 129.7, 128.2, 70.1, 58.7,
57.5, 56.9, 43.4, 36.0, 35.2, 29.6, 26.5, 16.2, 9.8. HRMS (ESI) m/z:
[M+ + 1] calculated for C25H35N4O4S, 487.2379; observed, 487.2369.
HPLC: tR = 4.4 min, k′ = 10.0.
(2S,4R)-1-((S)-2-(3,3-Dimethylbutanamido)-3,3-dimethylbutano-
yl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-car-
boxamide (5). Following the general synthesis method B, from
intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and 3,3-
dimethylbutanoic acid (22 mg, 24 μL, 0.19 mmol, 1 equiv), compound
5 was obtained as a white powder (58 mg, 0.11 mmol, 58%). 1H NMR
(CDCl3, 500 MHz): δ 8.68 (s, 1H), 7.39−7.32 (m, 5H), 6.05 (d, 1H, J
= 8 Hz), 4.71 (t, 1H, J = 10.0 Hz), 4.57−4.48 (m, 3H), 4.33 (dd, 1H, J
= 15.0, 5.0 Hz), 4.11 (d, 1H, J = 10 Hz), 3.58 (dd, 1H, J = 10.0, 5.0
Hz), 2.54−2.49 (m, 4H), 2.14−210 (m, 2H), 2.08−2.02 (m, 2H), 0.99
(s, 9H), 0.93 (s, 9H). 13C NMR (CDCl3, 125 MHz): δ 172.7, 172.1,
170.8, 150.5, 148.6, 138.2, 131.7, 131.1, 129.6, 128.3, 70.1, 58.5, 57.6,
56.8, 50.6, 43.4, 35.8, 34.8, 31.2, 29.9, 26.6, 16.2. HRMS (ESI) m/z:
[M+ + 1] calculated for C28H41N4O4S, 529.2848; observed, 529.2844.
HPLC: tR = 3.1 min, k′ = 9.4.
Figure 7. Co-crystal structures of second-series inhibitors. Crystal structure of VBC in complex with 15 (A, PDB 5LLI), 16 (B), 17 (C), 18 (D), and
19 (E) (purple carbons). VHL is shown as a pale-green surface and the VHL residues forming the binding pocket as orange stick representations.
Inhibitor-binding waters are shown as red spheres. Hydrogen bond interactions between inhibitors, bound waters, and VHL pocket residues are
shown as dashed red lines.
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carboxamide (6). Following the general synthesis method A, from
intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and cyclo-
propanecarboxylic acid anhydride (43 mg, 0.28 mmol, 1.5 equiv),
compound 6 was obtained as a white powder (51 mg, 0.10 mmol,
55%). 1H NMR (CDCl3, 500 MHz): δ 8.67 (s, 1H), 7.37−7.33 (m,
5H), 6.36 (d, 1H, J = 8 Hz), 4.70 (t, 1H, J = 10.0 Hz), 4.57−4.49 (m,
3H), 4.33 (dd, 1H, J = 15.0, 5.0 Hz), 4.06 (d, 1H, J = 10 Hz), 3.58 (dd,
1H, J = 10.0, 5.0 Hz), 2.51−2.46 (m, 4H), 2.12−2.08 (m, 1H), 1.40−
136 (m, 1H), 0.94 (s, 9H), 0.93−0.85 (m, 2H), 0.79−0.70 (m, 2H).
13C NMR (CDCl3, 125 MHz): δ 174.6, 172.1, 170.9, 150.5, 148.6,
138.2, 131.7, 131.1, 129.7, 128.3, 70.1, 58.6, 57.9, 56.8, 43.4, 36.0, 35.1,
26.5, 16.2, 14.8, 7.8. HRMS (ESI) m/z: [M+ + 1] calculated for




2-carboxamide (7). Following the general synthesis method A, from
deprotected intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and
Scheme 1a
aReagents and conditions: (i) N(Et)3, anhydride derivative, DCM, rt, 2 h; (ii) 4-chlorobutanoyl chloride, DCM/NaOH, rt, 1 h; KOtBu, THF, 0 °C−
rt, on; (iii) carboxylic acid derivative, HATU, DIPEA, DMF, rt, 1 h; (iv) TFA:DCM, rt, 30 min; (v) N(Et)3, acetic anhydride, DCM, rt, 2 h; (vi)
formaldehyde, DMF, rt, 90 min, NaBH(OAc)3, rt, 10 min; (vii) N(Et)3, acetic anhydride, DCM, rt, 2 h.
Scheme 2a
aReagents and conditions: (i) TFA:DCM, rt, 30 min; (ii) Boc-L-Ala, HATU, DIPEA, DMF, rt, 1 h; (iii) TFA:DCM, rt, 30 min; (iv) N(Et)3, acetic
anhydride, DCM, rt, 2 h; (v) Boc-L-Thr, HATU, DIPEA, DMF, rt, 1 h; (vi) 1-ﬂuorocyclopropanecarboxylic acid, HATU, DIPEA, DMF, rt, 1 h.
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triﬂuoroacetic anhydride (59 mg, 40 μL, 0.28 mmol, 1.5 equiv),
compound 7 was obtained as a white powder (59 mg, 0.11 mmol,
60%). 1H NMR (CDCl3, 500 MHz): δ 8.68 (s, 1H), 7.35 (q, 4H, J =
15.0, 10.0 Hz), 7.07−7.01 (m, 2H), 4.66 (t, 1H, J = 10.0 Hz), 4.60−
4.53 (m, 3H), 4.35 (dd, 1H, J = 15.0, 5.0 Hz), 3.84 (d, 1H, J = 10 Hz),
3.71 (dd, 1H, J = 10.0, 5.0 Hz), 2.50−2.46 (m, 4H), 2.14−2.10 (m,
1H), 0.96 (s, 9H). 13C NMR (CDCl3, 125 MHz): δ 170.6, 169.9,
157.2 (JCF = 37.0 Hz), 150.5, 148.6, 138.0, 131.7, 131.3, 129.7, 128.2,
115.9 (JCF = 286.0 Hz), 70.3, 59.2, 58.0, 57.0, 43.4, 36.4, 26.4, 16.2.
HRMS (ESI) m/z: [M+ + 1] calculated for C24H30F3N4O4S, 527.1940;
observed, 527.1933. HPLC: tR = 4.7 min, k′ = 8.4.
(2S,4R)-1-((S)-3,3-Dimethyl-2-(2,2,2-trichloroacetamido)-
butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-
2-carboxamide (8). Following the general synthesis method A, from
intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and trichloroacetic
anhydride (87 mg, 51 μL, 0.28 mmol, 1.5 equiv), compound 8 was
obtained as a white powder (70 mg, 0.12 mmol, 65%). 1H NMR
(CDCl3, 500 MHz): δ 8.68 (s, 1H), 7.38−7.33 (m, 5H), 7.12 (t, 1H, J
= 5.0 Hz), 4.70 (t, 1H, J = 10.0 Hz), 4.62 (s, 1H), 4.55−4.51 (m, 2H),
4.37 (dd, 1H, J = 15.0, 5.0 Hz), 3.87 (d, 1H, J = 10 Hz), 3.72 (dd, 1H,
J = 10.0, 5.0 Hz), 2.54−2.49 (m, 4H), 2.15−2.11 (m, 1H), 0.99 (s,
9H). 13C NMR (CDCl3, 125 MHz): δ 170.6, 170.2, 170.0, 150.5,
148.7, 138.0, 131.7, 131.2, 129.7, 128.3, 92.5, 70.4, 59.3, 59.1, 56.9,
43.5, 36.8, 36.3, 26.4, 16.2. HRMS (ESI) m/z: [M+ + 1] calculated for




2-carboxamide (9). Following the general synthesis method B, from
intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and 2-ﬂuoroisobutyric
acid (20 mg, 18 μL, 0.19 mmol, 1 equiv), compound 9 was obtained as
a light-orange powder (39 mg, 0.075 mmol, 40%). 1H NMR (CDCl3,
500 MHz): δ 8.68 (s, 1H), 7.37−7.32 (m, 5H), 6.99 (t, 1H, J = 5.0
Hz), 4.73 (t, 1H, J = 10.0 Hz), 4.58−4.53 (m, 2H), 4.45 (d, 1H, J =
10.0 Hz), 4.33 (dd, 1H, J = 15.0, 5.0 Hz), 4.02 (d, 1H, J = 10 Hz), 3.64
(dd, 1H, J = 10.0, 5.0 Hz), 2.56−2.51 (m, 4H), 2.14−2.09 (m, 1H),
1.53 (m, 6H), 0.94 (s, 9H). 13C NMR (CDCl3, 125 MHz): δ 173.7
(JCF = 21.0 Hz), 171.4, 170.7, 150.5, 148.6, 138.1, 131.7, 131.1, 129.7,
128.3, 96.2 (JCF = 180.0 Hz), 70.3, 58.6, 57.4, 56.7, 43.4, 35.9, 35.4,
26.5, 25.4 (JCF = 24.0 Hz), 24.7 (JCF = 24.0 Hz), 16.2. HRMS (ESI)
m/z: [M+ + 1] calculated for C26H36FN4O4S, 519.2441; observed,
519.2447. HPLC: tR = 4.7 min, k′ = 8.4.
(2S,4R)-1-((S)-2-(1-Fluorocyclopropanecarboxamido)-3,3-dime-
thylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-
pyrrolidine-2-carboxamide (10). Following the general synthesis
method B, from intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and 1-
ﬂuorocyclopropanecarboxylic acid (20 mg, 0.19 mmol, 1 equiv),
compound 10 was obtained as a white powder (51 mg, 0.10 mmol,
53%). 1H NMR (CDCl3, 400 MHz): δ 8.80 (s, 1H), 7.39−7.35 (m,
5H), 7.04−7.02 (m, 1H), 4.73 (t, 1H, J = 8.0 Hz), 4.59−4.52 (m, 3H),
4.33 (dd, 1H, J = 12.0, 4.0 Hz), 4.02 (d, 1H, J = 12 Hz), 3.64 (dd, 1H,
J = 12.0, 4.0 Hz), 2.54−2.48 (m, 4H), 2.14−2.08 (m, 1H), 1.35−1.25
(m, 4H), 0.97 (s, 9H). 13C NMR (CDCl3, 101 MHz): δ 171.3, 170.8,
170.5 (JCF = 20.0 Hz), 151.0, 147.6, 138.6, 132.3, 130.5, 129.6, 128.3,
79.5, 70.3, 58.7, 57.7, 56.8, 43.4, 36.1, 35.4, 26.5, 15.8, 13.9 (JCF = 11.0
Hz). HRMS (ESI) m/z: [M+ + 1] calculated for C26H34FN4O4S,
517.2285; observed, 517.2290. HPLC: tR = 3.4 min, k′ = 7.5.
(2S,4S)-1-((S)-2-(1-Fluorocyclopropanecarboxamido)-3,3-dime-
thylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-
pyrrolidine-2-carboxamide (cis-10). Following the general synthesis
method B, from intermediate 27 (300 mg, 0.56 mmol, 1 equiv) and 1-
ﬂuorocyclopropanecarboxylic (58 mg, 0.55 mmol, 1 equiv), compound
cis-10 was obtained as a white powder (137 mg, 0.26 mmol, 47%). 1H
NMR (CDCl3, 400 MHz): δ 8.68 (s, 1H), 7.47 (t, 1H, J = 8.0 Hz),
7.37 (q, 4H, J = 16.0, 8.0 Hz), 6.92 (m, 1H), 5.54 (d, 1H, J = 8.0 Hz),
4.75 (d, 1H, J = 12.0 Hz), 4.65 (dd, 1H, J = 12.0, 4.0 Hz), 4.55 (d, 1H,
Scheme 3a
aReagents and conditions: (i) TFA:DCM, rt, 30 min; (ii) 1-ﬂuorocyclopropanecarboxylic acid, HATU, DIPEA, DMF, rt, 1 h.
Figure 8. Correlations between cellular activity and physicochemical
parameters in vitro. Reported values are from Tables 2 and 3 for
inhibitors 1, 3, 6, 10, 15, and 16−19. (A) ITC pKd vs activity in cells.
(B) CHILogD7.4 vs PAMPA permeability. (C) relative cellular activity
vs permeability. HIF-1α protein levels measured using Western blot, as
proxy of cellular activity, and normalized to protein levels with
inhibitor 10.
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J = 12.0 Hz), 4.50−4.45 (m, 1H), 4.30 (dd, 1H, J = 16.0, 4.0 Hz), 3.88
(dd, 1H, J = 8.0, 4.0 Hz), 3.82 (d, 1H, J = 12.0 Hz), 2.52 (s, 3H), 2.38
(d, 1H, J = 14.0 Hz), 2.22−2.15 (m, 1H), 1.36−1.26 (m, 4H), 0.95 (s,
9H). 13C NMR (CDCl3, 101 MHz): δ 172.6, 171.8, 169.9 (JCF = 20.0
Hz), 150.5, 148.7, 137.3, 131.6, 131.5, 129.8, 128.4, 79.5, 71.2, 60.1,
58.8, 57.1, 43.7, 35.4, 35.1, 26.4, 16.1, 13.8 (JCF = 10.1 Hz). HRMS
(ESI) m/z: [M+ + 1] calculated for C26H34FN4O4S, 517.2285;
observed, 517.2278.
(2S,4R)-1-((S)-2-Acetamidopropanoyl)-4-hydroxy-N-(4-(4-methyl-
thiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (11). Following the
general synthesis method A, from the deprotected intermediate of 25
(102 mg, 0.19 mmol, 1 equiv) and acetic anhydride (27 μL, 29 mg,
0.28 mmol, 1.5 equiv), compound 11 was obtained as a white powder
(53 mg, 0.12 mmol, 65%). 1H NMR (CD3OD, 400 MHz): δ 8.88 (s,
1H), 7.46−7.41 (m, 4H), 4.65−4.60 (m, 1H), 4.58−4.50 (m, 3H),
4.46−4.39 (m, 2H), (3.78 (d, 2H, J = 4.0 Hz), 2.48 (s, 3H), 2.27−2.21
(m, 1H), 2.11−2.02 (m, 1H), 1.97 (s, 3H), 1.33 (d, 3H, J = 8.0 Hz).
13C NMR (CD3OD, 101 MHz): δ 174.5, 173.8, 172.9, 152.8, 149.1,
140.2, 133.4, 131.6, 130.4, 128.9, 70.1, 60.7, 56.4, 43.6, 39.0, 22.3, 16.9,
15.8. HRMS (ESI) m C21H27N4O4S/z: [M
+ + 1] calculated for




mide (12). To a solution of intermediate 22 (205 mg, 0.38 mmol) and
4-chlorobutanoyl chloride (0.069 mg, 56 μL, 0.49 mmol, 1.3 equiv) in
DCM (15 mL), a cold 1N solution of NaOH (6 mL) was added and
the resulting mixture was stirred vigorously for 20 min at room
temperature. The organic layer was collected and dried over MgSO4
and evaporated to aﬀord the intermediate crude compound. To a
solution of the intermediate crude compound in THF cooled to 0 °C
was added potassium tert-butoxide (128 mg, 1.14 mmol, 3 equiv), and
the mixture was allowed to warm to room temperature and stirred
overnight. Water was added, and the mixture was extracted with ethyl
acetate (3×). The combined organic phases were dried over MgSO4
and evaporated to aﬀord the corresponding crude compound that was
puriﬁed by ﬂash column chromatography using gradient elution of
10−70% acetone in heptane to yield the ﬁnal compound 12 as a white
powder (120 mg, 0.24 mmol, 63%). 1H NMR (CDCl3, 500 MHz): δ
8.68 (s, 1H), 7.37−7.32 (m, 5H), 4.74 (s, 1H), 4.70 (t, 1H, J = 10.0
Hz), 4.56−4.51 (m, 2H), 4.38 (dd, 1H, J = 15.0, 5.0 Hz), 4.01 (d, 1H,
J = 10 Hz), 3.75−3.64 (m, 2H), 3.58 (dd, 1H, J = 10.0, 5.0 Hz), 2.58−
2.51 (m, 4H), 2.41−2.35 (m, 1H), 2.31−2.25 (m, 1H), 2.11−2.0 (m,
1H), 1.99−193 (m, 2H), 1.00 (s, 9H). 13C NMR (CDCl3, 125 MHz):
δ 177.0, 171.9, 170.2, 150.5, 148.6, 138.2, 131.7, 131.1, 129.7, 128.2,
70.0, 59.2, 58.3, 56.6, 47.2, 43.4, 35.9, 35.8, 30.7, 27.7, 19.0, 16.2.
Table 3. Structures, Kds Measured by ITC, Calculated Ligand Eﬃciency (LE) [LE = −ΔG/NHA = −RT ln Kd/NHA],65 and
Ligand Lipophilic Eﬃciency (LLE) [LLE = pKd−Log D]
65 On the Basis of ITC Results, PAMPA Measured Passive
Permeability, Chromatographic Hydrophobicity Index log D (CHILogD7.4), Number of Hydrogen Bond Donors, Calculated
Topological Polar Surface Area (TPSA), and Number of Rotatable Bonds of Inhibitors 1, 3, 6, and 15−19
aPermeability of inhibitors were determined at room temperature by PAMPA, using propanolol (medium permeability −62.7 nm/s) as a control.
bValues calculated using StarDrop software.
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HRMS (ESI) m/z: [M+ + 1] calculated for C26H35N4O4S, 499.2379;
observed, 499.2382. HPLC: tR = 2.9 min, k′ = 8.7.
(2S,4R)-1-((S)-3,3-Dimethyl-2-(N-methylacetamido)butanoyl)-4-
hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxa-
mide (13). To a solution of deprotected intermediate 22 (100 mg,
0.23 mmol, 1 equiv) in DMF was added formaldehyde (18 μL, 7 mg,
0.23 mmol, 1 equiv). After stirring the solution for 90 min at room
temperature, NaBH(OAc)3 (74 mg, 0.35 mmol, 1.5 equiv) was added
and the resulting mixture was stirred for 10 min at room temperature.
Water was added, and the mixture was extracted with ethyl acetate
(3×). The combined organic phases were dried with MgSO4 and
evaporated to aﬀord the crude of the corresponding methylated
intermediate (100 mg, 0.22 mmol, 95%) that was used in the following
reaction without further puriﬁcation. Following the general synthesis
method A, using the methylated intermediate (100 mg, 0.22 mmol, 1
equiv) and acetic anhydride (32 μL, 34 mg, 0.34 mmol, 1.5 equiv),
compound 13 was obtained as a white powder (57 mg, 0.12 mmol,
52%). 1H NMR (CDCl3, 400 MHz): δ 8.67 (s, 1H), 7.38−7.32 (m,
5H), 5.21 (s, 1H), 4.72 (t, 1H, J = 8.0 Hz), 4.58−4.48 (m, 2H), 4.38
(dd, 1H, J = 12.0, 4.0 Hz), 3.96 (d, 1H, J = 8 Hz), 3.70−3.63 (m, 1H),
3.54 (dd, 1H, J = 12.0, 4.0 Hz), 3.15 (s, 3H), 2.66−2.60 (m, 1H), 2.52
(s, 3H), 2.11−2.04 (m, 4H), 1.00 (s, 9H). 13C NMR (CDCl3, 101
MHz): δ 172.8, 170.9, 170.8, 150.4, 148.7, 138.2, 131.7, 131.1, 129.7,
128.2, 70.2, 59.3, 58.3, 56.0, 44.8, 43.4, 36.3, 35.7, 34.5, 27.8, 22.4,
16.2. HRMS (ESI) m/z: [M+ + 1] calculated for C25H35N4O4S,
487.2379; observed, 487.2390. HPLC: tR = 2.9 min, k′ = 8.7.
(2S,4R)-1-((2S,3S)-2-(1-Fluorocyclopropanecarboxamido)-3-hy-
droxybutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-
pyrrolidine-2-carboxamide (14). Following the general synthesis
method B, from the deprotected intermediate of 26 (100 mg, 0.19
mmol, 1 equiv) and 1-ﬂuorocyclopropanecarboxylic acid (20 mg, 0.19
mmol, 1 equiv), compound 14 was obtained as a white powder (45
mg, 0.090 mmol, 48%). 1H NMR (DMSO-d6, 400 MHz): δ 9.01 (s,
1H), 8.44−8.41 (m, 1H), 7.76 (d, 1H, J = 8.0 Hz), 7.43 (d, 2H, J = 8.0
Hz), 7.35 (d, 2H, J = 8.0 Hz), 4.52−4.49 (m, 1H), 4.46−4.42 (m, 1H),
4.35−4.28 (m, 2H), 4.00−3.94 (m, 1H), 3.74−3.66 (m, 2H), 2.45 (s,
3H), 2.09−2.05 (m, 1H), 1.93−1.87 (m, 1H), 1.36−1.28 (m, 2H),
1.23−1.14 (m, 2H), 1.12 (d, 3H, J = 8.0 Hz). 13C NMR (DMSO-d6,
101 MHz): δ 171.5, 168.7, 168.4 (JCF = 20.0 Hz), 151.6, 147.6, 139.3,
131.2, 129.7, 128.8, 127.5, 77.9 (JCF = 234.0 Hz), 68.8, 66.6, 58.8, 56.9,
55.6, 41.6, 37.9, 19.4, 15.9, 12.8 (JCF = 11.0 Hz). HRMS (ESI) m/z:
[M+ + 1] calculated for C24H30FN4O5S, 505.1921; observed, 505.1928.
HPLC: tR = 3.2 min, k′ = 7.0.
(2S,4R)-1-((S)-2-(1-Acetylcyclopropanecarboxamido)-3,3-dime-
thylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-
pyrrolidine-2-carboxamide (16). Following the general synthesis
method B, from intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and 1-
acetylcyclopropanecarboxylic acid (24 mg, 0.19 mmol, 1 equiv),
compound 16 was obtained as a white powder (51 mg, 0.094 mmol,
50%). 1H NMR (CDCl3, 400 MHz): δ 9.75 (d, 1H, J = 8.0 Hz), 8.68
(s, 1H), 7.60−7.58 (m, 1H), 7.35 (q, 4H, J = 16.0, 8.0 Hz), 4.78 (t,
1H, J = 8.0 Hz), 4.57 (dd, 1H, J = 12.0, 4.0 Hz), 4.46 (s, 1H), 4.32−
4.25 (m, 2H), 4.17 (d, 1H, J = 8.0 Hz), 3.50 (m, 1H), 2.65−2.58 (m,
1H), 2.52 (s, 3H), 2.12−2.07 (m, 1H), 1.94 (s, 3H), 1.83−1.76 (m,
2H), 1.56−1.49 (m, 2H), 0.98 (s, 9H). 13C NMR (CDCl3, 101 MHz):
Table 4. Structures, Association (kon), and Dissociation (koff) Rate Constants Determined by Surface Plasmon Resonance
(SPR), Kds Determined by SPR (Kd = koff/kon), Calculated Dissociative Half-Times (t1/2), and Microsomal and Plasma Stability
of Inhibitors 1, 10, 15, 16, and 18
aDissociative half-life of inhibitor−VBC binary complex calculated based on inhibitor dissociation rate constants (koff), t1/2 = ln2/koff.
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Figure 9. Activity in cells vs half-life dissociation from VBC protein
complex. Values shown are for inhibitors 1, 3, 6, 10, 15, and 16−19 at
10 °C (squares) and at 20 °C (triangles). HIF-1α protein levels
measured using Western blot, as proxy of cellular activity, and
normalized to protein levels with inhibitor 10.
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δ 207.7, 172.4, 170.5, 170.2, 150.4, 148.7, 138.2, 131.7, 131.1, 129.7,
128.4, 70.3, 59.3, 58.0, 56.4, 43.5, 35.5, 34.2, 26.7, 25.0, 19.9, 16.2.
HRMS (ESI) m/z: [M+ + 1] calculated for C28H37N4O5S, 541.2484;
observed, 541.2485. HPLC: tR = 3.3 min, k′ = 7.2.
Ethyl 1-Aminocyclopropanecarboxylate. Ethanol (2 mL) was
added to a round-bottom ﬂask and cooled to 0 °C, then thionyl
chloride (706 mg, 430 μL, 5.94 mmol, 2 equiv) was added dropwise
and the mixture was stirred for 15 min. 1-Aminocyclopropanecarbox-
ylic (300 mg, 2.97 mmol, 1 equiv) acid was added, and the mixture was
reﬂuxed for 2 h. Solvent was removed, and the ﬁnal compound 5 was
obtained as a white powder (363 mg, 2.82 mmol, 95%). 1H NMR
(DMSO-d6, 400 MHz): δ 9.11 (s, 2H), 4.16 (q, 2H, J = 12.0, 4.0 Hz),
1.51−1.47 (m, 2H), 1.39−1.36 (m, 2H), 1.21 (t, 3H, J = 8.0 Hz). 13C
NMR (DMSO-d6, 101 MHz): δ 170.0, 62.3, 34.0, 14.4, 13.6.
Ethyl 1-Acetamidocyclopropanecarboxylate. Following the gen-
eral protocol for the synthesis of ﬁnal inhibitors by acylation, from
intermediate 5 (100 mg, 0.77 mmol, 1 equiv) and acetic anhydride
(118 mg, 110 μL, 1.15 mmol, 1.5 equiv), compound 6 was obtained as
a pale-lime powder (80 mg, 0.47 mmol, 62%). 1H NMR (DMSO-d6,
400 MHz): δ 8.44 (s, 1H), 4.02 (q, 2H, J = 12.0, 4.0 Hz), 1.79 (s, 3H),
1.33−1.30 (m, 2H), 1.14 (t, 3H, J = 8.0 Hz), 0.98−0.95 (m, 2H). 13C
NMR (DMSO-d6, 101 MHz): δ 172.1, 170.2, 60.5, 32.8, 22.4, 16.5,
14.1.
1-Acetamidocyclopropanecarboxylic Acid. To a solution of
compound 6 (70 mg, 0.41 mmol, 1 equiv) in methanol was added
an aqueous solution of NaOH (1N), and the resulting mixture was
then heated at 100 °C for 4 h. Methanol was evaporated, and the
resulting solution was acidiﬁed and extracted with DCM (5×). The
combined organic phases were dried over MgSO4 and evaporated to
aﬀord the corresponding ﬁnal compound 7 as a white powder (53 mg,
0.37 mmol, 91%). 1H NMR (DMSO-d6, 400 MHz): δ 12.25 (s, 1H),
8.35 (s, 1H), 1.77 (s, 3H), 1.30−1.28 (m, 2H), 0.94−0.91 (m, 2H).
13C NMR (DMSO-d6, 101 MHz): δ 174.0, 170.1, 32.5, 22.3, 16.3.
(2S,4R)-1-((S)-2-(1-Acetamidocyclopropanecarboxamido)-3,3-di-
methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-
pyrrolidine-2-carboxamide (17). Following the general synthesis
method B, from intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and 1-
acetamidocyclopropanecarboxylic acid (27 mg, 0.19 mmol, 1 equiv),
compound 17 was obtained as a white powder (49 mg, 0.088 mmol,
47%). 1H NMR (CDCl3, 400 MHz): δ 8.68 (s, 1H), 7.41−7.32 (m,
5H), 7.11 (d, 1H, J = 8.0 Hz), 6.35 (s, 1H), 4.74 (t, 1H, J = 8.0 Hz),
4.55−4.50 (m, 2H), 4.40−4.33 (m, 2H), 4.08 (d, 1H, J = 8.0 Hz), 3.57
(m, 1H), 2.57−2.52 (m, 4H), 2.16−2.10 (m, 1H), 2.02 (s, 3H), 1.57−
1.52 (m, 1H), 1.46−1.41 (m, 1H), 1.25−1.22 (m, 1H), 1.07−1.01 (m,
1H), 0.93 (s, 9H). 13C NMR (CDCl3, 101 MHz): δ 172.1, 172.0,
171.8, 170.7, 150.4, 148.7, 138.2, 131.7, 131.2, 129.7, 128.3, 70.2, 58.4,
56.8, 43.4, 35.9, 35.5, 35.0, 26.5, 23.4, 17.5, 16.9, 16.2. HRMS (ESI)
m/z: [M+ + 1] calculated for C28H38N5O5S, 556.2594; observed,
556.2606. HPLC: tR = 3.3 min, k′ = 7.2.
(2S,4R)-1-((S)-2-(Cyclobutanecarboxamido)-3,3-dimethylbutano-
yl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-car-
boxamide (18). Following the general synthesis method B, from
intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and cyclo-
butanecarboxylic acid (19 mg, 18 μL, 0.19 mmol, 1 equiv), compound
18 was obtained as a white powder (58 mg, 0.11 mmol, 58%). 1H
NMR (CDCl3, 400 MHz): δ 8.68 (s, 1H), 7.38−7.31 (m, 5H), 5.93
(d, 1H, J = 8.0 Hz), 4.74 (t, 1H, J = 8.0 Hz), 4.60−4.54 (m, 2H), 4.46
(d, 1H, J = 8.0 Hz), 4.33 (dd, 1H, J = 12.0, 4.0 Hz), 4.14 (d, 1H, J =
8.0 Hz), 3.59 (m, 1H), 3.06−2.97 (m, 1H), 2.62−2.56 (m, 1H), 2.52
(s, 3H), 2.25−2.11 (m, 5H), 2.01−1.91 (m, 2H), 0.92 (s, 9H). 13C
NMR (CDCl3, 101 MHz): δ 175.9, 172.3, 170.6, 150.5, 138.2, 131.2,
129.7, 128.3, 70.2, 58.4, 57.6, 56.7, 43.4, 39.7, 35.7, 34.8, 26.5, 25.7,
25.2, 18.3, 16.2. HRMS (ESI) m/z: [M+ + 1] calculated for




2-carboxamide (19). Following the general synthesis method B, from
intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and oxetane-3-
carboxylic acid (19 mg, 0.19 mmol, 1 equiv), compound 19 was
obtained as a white powder (51 mg, 0.10 mmol, 53%). 1H NMR
(CDCl3, 400 MHz): δ 8.68 (s, 1H), 7.36 (q, 4H, J = 16.0, 8.0 Hz),
7.17 (m, 1H), 6.07 (d, 1H, J = 8.0 Hz), 4.81−4.70 (m, 5H), 4.61−4.53
(m, 3H), 4.33 (dd, 1H, J = 12.0, 4.0 Hz), 4.09 (d, 1H, J = 8.0 Hz),
3.74−3.67 (m, 1H), 3.65−3.61 (m, 1H), 2.63−2.56 (m, 1H), 2.52 (s,
3H), 2.17−2.11 (m, 1H), 0.93 (s, 9H). 13C NMR (CDCl3, 101 MHz):
δ 172.1, 171.8, 170.5, 150.5, 138.1, 131.7, 131.2, 129.7, 128.3, 73.3,
70.4, 58.6, 57.8, 56.8, 43.5, 40.3, 35.9, 35.1, 26.5, 16.2. HRMS (ESI)
m/z: [M+ + 1] calculated for C26H35N4O5S, 515.2328; observed,
515.2344. HPLC: tR = 2.8 min, k′ = 8.3.
(2S,4R)-1-((S)-3,3-Dimethyl-2-(3-oxocyclobutanecarboxamido)-
butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-
2-carboxamide (20). Following the general synthesis method B, from
intermediate 22 (102 mg, 0.19 mmol, 1 equiv) and 3-oxocyclobuta-
necarboxylic acid (21 mg, 0.19 mmol, 1 equiv), compound 20 was
obtained as a white powder (53 mg, 0.10 mmol, 54%). 1H NMR
(CDCl3, 400 MHz): δ 8.68 (s, 1H), 7.36 (q, 4H, J = 16.0, 8.0 Hz),
7.16 (m, 1H), 6.23 (d, 1H, J = 8.0 Hz), 4.72 (t, 1H, J = 8.0 Hz), 4.62−
4.53 (m, 3H), 4.33 (dd, 1H, J = 12.0, 4.0 Hz), 4.05 (d, 1H, J = 8.0 Hz),
3.64 (m, 1H), 3.43−3.39 (m, 2H), 3.27−3.13 (m, 2H), 3.08−3.00 (m,
1H), 2.62−2.57 (m, 1H), 2.52 (s, 3H), 2.16−2.11 (m, 1H), 0.94 (s,
9H). 13C NMR (CDCl3, 101 MHz): δ 182.4, 173.8, 171.8, 170.5,
150.5, 148.7, 138.1, 131.7, 131.3, 129.7, 128.3, 70.4, 58.6, 58.1, 56.8,
51.8, 43.5, 35.9, 35.2, 28.7, 26.5, 16.2. HRMS (ESI) m/z: [M+ + 1]
calculated for C27H35N4O5S, 527.2328; observed, 527.2332. HPLC: tR
= 2.9 min, k′ = 8.7.
(2S,4R)-1-((S)-2-(1-Acetylazetidine-3-carboxamido)-3,3-dimethyl-
butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-
2-carboxamide (21). Following the general synthesis method A, from
the deprotected intermediate of 23 (102 mg, 0.17 mmol, 1 equiv) and
acetic anhydride (25 mg, 24 μL, 0.25 mmol, 1.5 equiv), compound 21
was obtained as a white powder (41 mg, 0.075 mmol, 45%). 1H NMR
(CDCl3, 400 MHz): δ 8.68 (s, 1H), 7.35 (m, 4H), 7.18 (m, 1H), 6.29
(dd, 1H, J = 60.0, 8.0 Hz), 4.70 (t, 1H, J = 8.0 Hz), 4.56−4.52 (m,
3H), 4.39−4.29 (m, 2H), 4.22−4.14 (m, 2H), 4.10−3.98 (m, 3H),
3.64 (d, 1H, J = 8.0 Hz) 3.31−3.23 (m, 1H), 2.59−2.44 (m, 4H),
2.18−2.11 (m, 1H), 1.83(d, 3H, J = 8.0 Hz), 0.93 (s, 9H). 13C NMR
(CDCl3, 101 MHz): δ 171.9, 171.6, 171.0, 170.6, 150.4, 148.6, 138.1,
131.2, 131.7, 129.6, 128.2, 70.2, 58.6, 58.0, 56.9, 52.5, 43.4, 36.5, 36.0,
35.4, 32.7, 26.5, 18.7, 16.2. HRMS (ESI) m/z: [M+ + 1] calculated for




yl)carbamoyl)azetidine-1-carboxylate (23). Following the general
synthesis method A, from intermediate 22 (102 mg, 0.19 mmol, 1
equiv) and 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (38 mg,
0.19 mmol, 1 equiv), compound 23 was obtained as a lime powder (69
mg, 0.11 mmol, 60%). 1H NMR (CDCl3, 400 MHz): δ 8.67 (s, 1H),
7.35 (q, 4H, J = 16.0, 8.0 Hz), 7.24 (m, 1H), 6.19 (d, 1H, J = 8.0 Hz),
4.70 (t, 1H, J = 8.0 Hz), 4.58−4.52 (m, 3H), 4.34 (dd, 1H, J = 12.0,
4.0 Hz), 4.07−3.97 (m, 4H), 3.63 (m, 1H), 3.22−3.15 (m, 1H), 2.56−
2.50 (m, 4H), 2.16−2.11 (m, 4H), 1.41 (s, 9H), 0.93 (s, 9H). 13C
NMR (CDCl3, 101 MHz): δ 172.3, 171.6, 170.7, 156.2, 150.4, 148.6,
138.1, 131.2, 129.7, 128.3, 80.0, 70.3, 58.7, 57.9, 56.9, 43.4, 36.1, 35.3,
33.4, 31.0, 28.5, 26.5, 16.2. HRMS (ESI) m/z: [M+ + 1] calculated for
C31H44N5O6S, 614.2934; observed, 614.3007.
tert-Butyl((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)-
benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)carbamate
(25). Following the general synthesis method B, from intermediate 24
(300 mg, 0.72 mmol, 1 equiv) and Boc-L-Ala (132 mg, 0.72 mmol, 1
equiv), compound 25 was obtained as a white solid (267 mg, 0.55
mmol, 78%). 1H NMR (CD3OD, 400 MHz): δ 9.15 (s, 1H), 7.49−
7.44 (m, 4H), 4.59 (t, 1H, J = 8.0 Hz), 4.51 (m, 1H), 4.47−4.35 (m,
3H), 3.78 (m, 2H), 2.51 (s, 3H), 2.28−2.22 (m, 1H), 2.08−2.02 (m,
1H), 1.43 (s, 9H), 1.30 (d, 3H, J = 8.0 Hz). 13C NMR (CD3OD, 101
MHz): δ 174.5, 172.0, 153.7, 147.5, 140.8, 130.7, 130.5, 129.0, 80.6,
71.1, 60.8, 56.4, 43.6, 38.9, 28.7, 17.2, 15.1. HRMS (ESI) m/z: [M+ +
1] calculated for C24H33N4O5S, 489.2166; observed, 489.2176.
tert-Butyl 2-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)-
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amino)-2-oxoacetate (26). Following the general synthesis method B,
from intermediate 24 (200 mg, 0.46 mmol, 1 equiv) and Boc-L-
threonine (102 mg, 0.46 mmol, 1 equiv), compound 26 was obtained
as a white powder (192 mg, 0.37 mmol, 80%). 1H NMR (DMSO-d6,
400 MHz): δ 8.98 (s, 1H), 8.39 (m, 1H), 7.41 (d, 2H, J = 8.0 Hz),
7.34 (d, 2H, J = 8.0 Hz), 6.49 (d, 1H, J = 8.0 Hz), 5.11, (s, 1H), 4.68
(d, 1H, J = 8.0 Hz), 4.43 (t, 1H, J = 8.0 Hz), 4.34−4.29 (m, 3H), 4.17
(t, 1H, J = 8.0 Hz), 3.85−3.80 (m, 1H), 3.73−3.62 (m, 2H), 2.45 (s,
3H), 2.08−2.04 (m, 1H), 1.93−1.87 (m, 1H), 1.38 (s, 9H), 1.05 (d,
3H, J = 8.0 Hz). 13C NMR (DMSO-d6, 101 MHz): δ 171.7, 169.7,
155.3, 151.5, 147.8, 139.3, 131.1, 129.8, 128.8, 127.5, 78.1, 68.8, 66.9,
58.8, 57.9, 55.5, 41.6, 37.8, 30.7, 28.2, 19.3, 16.0. HRMS (ESI) m/z:
[M+ + 1] calculated for C25H35N4O6S, 519.2277; observed, 519.2285.
Fluorescence Polarization (FP). FP competitive binding experi-
ments were performed on a PHERAstar FS (BMG LABTECH) in
384-well plates (Corning 3575), with an excitation wavelength (λ) at
485 nm and emission λ at 520 nm. Each well solution (15 μL)
contained 15 nM of VBC protein, 10 nM of FAM-labeled HIF-1α
peptide (FAM-DEALAHypYIPMDDDFQLRSF, Kd = 3 nM as
measured by a direct FP titration), and decreasing concentrations of
compound (14-point serial 2-fold dilutions starting from 50 μM) in
100 mM Bis-tris, 100 mM NaCl, 1 mM DTT, pH 7. Control wells
contained VBC and peptide in the absence of compound (maximum
signal) and peptide in the absence of protein (background signal).
Data were obtained in triplicate, and the percentage of displacement
was determined and graphed against log[VHL inhibitors]. Average
IC50 values and the standard error of the mean (SEM) were
determined for each titration using Prism 6. Dissociation constants Kd
were back-calculated from the measured IC50 values using a
displacement binding model, as described previously.17
Isothermal Titration Calorimetry (ITC). ITC experiments were
carried in an ITC200 microcalorimeter (GE Healthcare). The
compounds were diluted from DMSO stock solution to 300 μM in
a buﬀer of 20 mM Bis-Tris propane, 150 mM NaCl, 1 mM DTT, pH
7. The compounds were titrated against 30 μM VBC complex,
equilibrated in the same buﬀer. The ﬁnal concentration of DMSO in
each experiment was 3% (v/v). The titrations consisted of 20
injections of 2 μL of ligand solution at a rate of 0.5 μL/s at 120 s time
intervals. An initial injection of ligand (0.4 μL) was made and
discarded during data analysis. All experiments were performed at
25°C while stirring at 750 rpm. The data were ﬁtted to a single-
binding-site model using the Microcal LLC ITC200 Origin software
provided by the manufacturer to obtain the stoichiometry n, the
dissociation constant Kd, and the enthalpy of binding ΔH.
Cell Culture and Cell Treatment. Human cervical carcinoma cell
HeLa was obtained from ATCC and propagated in DMEM
supplemented with 10% fetal bovine serum (FBS), L-glutamine, and
100 μg/mL of penicillin/streptomycin at 37 °C. HeLa cells were
routinely tested for mycoplasma contamination using MycoAlert kit
from Lonza. Cells were treated with VHL inhibitors at 50 μM for 2 h
in fresh medium, and 1% DMSO was used as vehicle control.
Immunoblotting. Cells were lysed in RIPA buﬀer (50 mM Tris
pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS, 250 M Na3VO4, 10 mM NaF) and a protease inhibitor cocktail
(Roche) per 10 mL of buﬀer. Proteins were resolved using sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS−PAGE),
transferred onto nitrocellulose membranes, and detected using primary
antibodies, with β-actin as loading control. Primary antibodies were
used at following dilutions for mammalian cells: anti-HIF-1α (BD
Biosciences, 610958, 1:1000), antihydroxy-HIF-1α (Hyp564) (Cell
Signaling Technology, no. 3434, 1:1000), and anti-β-actin (Cell
Signaling Technology, no. 3700s, 1:10000). Following primary
antibody incubation, a goat antimouse (LI-COR, 926-32210,
1:10,000) or donkey antirabbit (LI-COR, 926−32213, 1:10000)
conjugated to IRDye 800CW secondary antibody were used for
detection on the LI-COR Odyssey (LI-COR, Bad Homburgh,
Germany).
Proliferation Assay. First, 1.5 × 105 cells were seeded in six-well
plates 1 day prior to treatments with VHL compounds. At treatment
times of 0, 24, 48, and 72 h, cells were then trypsinized using 400 μL of
trypsin, followed by 600 μL of media. Cells were then counted using
hemocytometer.
Colony Formation Assay. First, 500−2000 cells were seeded in a
six-well plate 1 day prior to treatments with VHL compounds. After 24
h of treatment, media was then changed and cells were further
incubated for 1 week. Cells were washed with PBS twice and stained
with 0.005% (w/v) crystal violet in 25% (v/v) methanol for 10 min at
room temperature. The staining was washed oﬀ with water, and plates
were left to dry overnight. Numbers of colonies formed were counted
with M-tools suite from OMERO on the scanned plates.
X-ray Crystallography. The VBC ternary complex was puriﬁed
and crystallized as described previously.17,52 Equal volume solutions of
VBC (∼5 mg/mL) and liquor solution were mixed in the hanging-
drop vapor diﬀusion method at 18 °C. The liquor solution contained
0.1 mM sodium cacodylate, pH 6.2−6.6, 16−18% polyethylene glycol
3350, 0.2 M magnesium acetate, and 10 mM DTT. The drop was
streaked with seeds of disrupted VBC crystals, and a 2−3 mm layer of
Al’s Oil (Hampton Research) was applied on top of the liquor solution
to slow the vapor diﬀusion rate. To obtain the structures of VHL
inhibitors bound to VBC, crystals were soaked overnight in a 1 mM
solution of inhibitor in 1% DMSO, 4% 2-propanol, and 95% liquor
solution. Crystals were screened using an in-house Rigaku M007HF X-
ray generator and Saturn 944HG+ CCD detector. X-ray data were
collected at 100 K at Diamond Light Source beamline I04−1. Indexing
and integration of reﬂections was performed using XDS with the
XDSGUI interface70 and scaling and merging with AIMLESS in
CCP4i.71,72 The isomorphous data sets were reﬁned using REFMAC5
(refs 73,74) and COOT (ref 75) using a template structure derived
from the Protein Data Bank (PDB) entry 1vcb (ref 76). Ligand
structures and restraints were generated using the PRODRG server.77
The MOLPROBITY server was used to validate the geometry and
steric clashes in the structures.78 The structures have been deposited in
the PDB with accession codes 5NVV, 5NVW, 5NVX, 5NVY, 5NVZ,
5NW0, 5NW1, and 5NW2, and data collection and reﬁnement
statistics are presented in Supporting Information, Table 1.
Parallel Artiﬁcial Membrane Permeability Assay (PAMPA).
PAMPA was performed using a 96-well precoated BD Gentest
PAMPA plate (BD Biosciences, UK). Each well was divided into two
chambers: donor and acceptor, separated by a lipid−oil−lipid trilayer
constructed in a porous ﬁlter. The eﬀective permeability, Pe, of the
compound was measured at pH 7.4. Stock solutions (5 mM) of the
compound were prepared in DMSO. The compound was then further
diluted to 10 μM in PBS, pH 7.4. The ﬁnal DMSO concentration did
not exceed 5% (v/v). The compound dissolved in PBS was then added
to the donor side of the membrane and PBS without compound was
added to the acceptor side. The PAMPA plate was left at room
temperature for 5 h, after which time, an aliquot (100 μL) was
removed from both acceptor and donor compartments and mixed with
acetonitrile (80 μL) containing an internal standard. The samples were
centrifuged (10 min, 5 °C, 3270 g) to sediment precipitated protein
and then sealed prior to UPLC-MS/MS analysis using a Quattro


















where: CA(t) = peak area of compound present in acceptor well at
time t = 18000 s, Cequiv = [CD(t) × VD + CA(t) × VA]/(VD + VA),
CD(t) = peak area of compound present in donor well at time t =
18000 s, A = ﬁlter area, VD = donor-well volume, VA = acceptor-well
volume, t = incubation time. Recovery of compound from donor and
acceptor wells was calculated, and data was only accepted when
recovery exceeded 70%.
CHILogD7.4 Measurement. The CHIlogD (chromatographic
hydrophobicity index log D) at pH 7.4 was determined using
retention time measurements on a HPLC Dionex system (Thermo
Fisher) with a Luna C18 column (Phenomenex). Test samples in
DMSO (10 mM) were diluted to a concentration of 0.25 mM using
50:50 acetonitrile:water. Mobile phase A was 10 mM ammonium
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acetate solution (pH 7.4), and mobile phase B was acetonitrile. HPLC
method was as follows: 1 mL/min ﬂow, temperature 20 °C, injection
volume 10 μL, gradient 0−10.5 min 100% A, 10.5−14 min 100% B,
14−15 min 100% A. A calibration line was generated using a test mix
of compounds (paracetamol, theophylline, caﬀeine, benzimidiazole,
colchicine, carbamazepine, indole, propiophenone, butyrophenone,
valerophenone, and heptanophenone). The CHIlogD was calculated
as previously described.79,80
Intracellular Drug Concentration.66 Brieﬂy, HeLa cells (1 × 106
cells/2 mL per well, 6-well plate) were incubated with known
concentration of compounds (50 μM) for 2 h at 37 °C before being
washed and lysed using lysis buﬀer (20 mM Tris, 150 mM, NaCl, 1%
Triton X100, and 1 pill per 10 mL of proteases inhibitors (Roche)).
The lysate was resuspended in 2 mL of ice-cold PBS. Resuspended
lysate (100 μL) was then subjected to solvent crash in a 1:2 ratio of
lysate to acetonitrile containing internal standard 5 ng/mL of
donepezil. The concentration was determined with the aid of an
appropriate calibration curve and UPLC-MS/MS. The unbound
intracellular compound concentration (free fraction) was determined
by dialyzing 150 μL of resuspended cell lysate against isotonic
phosphate buﬀer in an equilibrium dialysis equipment. This was also
subjected to UPLC-MS/MS.
Surface Plasmon Resonance (SPR). VHL inhibitors were
dissolved in DMSO (1 mM) and then diluted 20-fold in DMSO to
achieve a 50 μM ﬁnal stock concentration. Ligand stock solution was
serially diluted 2-fold (ﬁve times) in DMSO, and the obtained
solutions were then diluted individually in SPR buﬀer (20 mM
HEPES, 150 mM NaCl, 1 mM DDT, 0.005% Tween P20, pH 7.0) to
obtain the ﬁnal 2% (v/v) DMSO concentration series from 1 μM to
31.25 nM (2-fold dilutions) and transferred to a 96-well plate. The
experiment was conducted in a Biacore T100 (GE Healthcare, Biacore,
Uppsala, Sweden) at 10 and 20 °C, and solutions were injected
individually using 60 and 160 s association and dissociation times,
respectively. Data were treated using Biacore T100 evaluation software
provided by the manufacturer. Reference ﬂow-cell response was
subtracted from the sample response with immobilized VBC protein
to correct for systematic noise and baseline drift. Data were solvent
corrected, and the response from the blank injections was used to
double reference the binding data. The data were normalized by
molecular weight, and rate constants kon and koff values were obtained
using a 1:1 binding model ﬁt.
Intrinsic Clearance (Cli) Experiments. Test compound (0.5 μM)
was incubated with female CD1 mouse liver microsomes (Xenotech
LLC; 0.5 mg/mL 50 mM potassium phosphate buﬀer, pH 7.4) and the
reaction started with addition of excess NADPH (8 mg/mL 50 mM
potassium phosphate buﬀer, pH 7.4). Immediately, at time zero, then
at 3, 6, 9, 15, and 30 min, an aliquot (50 μL) of the incubation mixture
was removed and mixed with acetonitrile (100 μL) to stop the
reaction. Internal standard was added to all samples, the samples were
centrifuged to sediment precipitated protein, and the plates then
sealed prior to UPLCMSMS analysis using a Quattro Premier XE
(Waters Corporation, USA).
XLﬁt (IDBS, UK) was used to calculate the exponential decay and
consequently the rate constant (k) from the ratio of peak area of test
compound to internal standard at each time point. The rate of intrinsic
clearance (CLi) of each test compound was then calculated using the
following calculation:
= × ×k VCL (mL/min/g liver) microsomal protein yieldi
where V (mL/mg protein) is the incubation volume/mg protein added
and microsomal protein yield is taken as 52.5 mg protein/g liver.
Verapamil (0.5 μM) was used as a positive control to conﬁrm
acceptable assay performance.
Plasma Stability (Plas Stab) Experiments. Test compound (50
μM) was incubated in prewarmed plasma at 37 °C (that is buﬀered to
pH 7.4 in ratio of 70:30 plasma to buﬀer). Immediately, at time zero,
then at 30, 60, 120, and 180 min, a 50 μL aliquot of the incubation
mixture was removed and mixed with 200 μL of acetonitrile containing
Donepezil as the internal standard (50 ng/mL) to stop the reaction.
The samples were centrifuged to sediment the precipitated protein and
the plates then sealed prior to UPLC-MS/MS analysis using a Quattro
Premier XE (Waters Corporation, USA).
XLﬁt (IDBS, UK) was used to calculate the exponential decay and
consequently the rate constant (k) from the ratio of peak area of test
compound to internal standard at each time point. The half-life was
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Supplementary ﬁgures, FP displacement assay data, ITC
data, SPR sensograms, crystallographic reﬁnement data,
NMR data and Western Blots from HIF-1α stabilization
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Accession Codes
PDB accession codes of VBC in complex with 3, 6, 10, 11, 16,
17, 18, and 19 are 5NVV, 5NVW, 5NVX, 5NVY, 5NVZ,
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